Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

@article{Smith2010Phase1C,
  title={Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.},
  author={Larry R Smith and Mary K Wloch and Ming Ye and Luane R Reyes and Souphaphone Boutsaboualoy and Casey E. Dunne and Jennifer A. Chaplin and Denis Rusalov and Alain P. Rolland and Cindy L Fisher and Mohamed S Al-Ibrahim and Martin L. Kabongo and Roy T. Steigbigel and Robert B. Belshe and Ernest R Kitt and Alice Chu and Ronald B. Moss},
  journal={Vaccine},
  year={2010},
  volume={28 13},
  pages={2565-72}
}
BACKGROUND Development of vaccines against highly pathogenic avian influenza virus H5N1 subtypes posing a pandemic threat remains a priority. Limitations in manufacturing capacity and production time of conventional inactivated vaccines highlight the need for additional approaches. METHODS We conducted two double-blind, placebo-controlled phase 1 studies involving a total of 103 healthy adults who received two intramuscular injections of Vaxfectin-adjuvanted plasmid DNA vaccine or placebo 21… CONTINUE READING
54 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…